Share
As the desire for a less frequently administered growth hormone treatment intensifies, clinicians are looking to researchers for the latest data on safety and efficacy. Luckily, as more studies are undertaken patients and clinicians may soon have a wealth of options. Since 1985, children with growth hormone deficiency (GHD) have been prescribed somatropin – recombinant...
Share
ENDO 2022 saw the presentation of positive clinical data from the open-label extensions (OLEs) of two of the Phase 3 trials of oral octreotide for patients with acromegaly. Amryt is marketing the drug as Mycapssa. Data presented in a late-breaking poster presentation of the 2nd year of the OLE of OPTIMAL (NCT03252353), a randomized, double-blind...
Share
What Is the Role of “Growth Hormone” When You Have Stopped Growing? Growth hormone clearly plays a key role in development during youth, but research in adults implicates it as an agent in cellular aging processes. Shlomo Melmed, MD, ChB, the first recipient of the Transatlantic Alliance Award, co-sponsored by the Endocrine Society and the...
Share
Growth hormone deficiency (GHD) among adults is associated with greater medical costs and an increased rate of other health conditions compared with those without GHD, according to industry-sponsored research presented at ENDO 2022 in Atlanta. Researchers led by Alden Smith, PharmD, Global Head of Health Economics and Outcomes Research at Ascendis Pharma in Palo Alto,...
Share
In November, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorization for Ascendis Pharma’s lonapegsomatropin (TransCon hGH), a long-acting once-weekly, transiently pegylated somatropin that in the body releases somatropin, indicated for growth failure in children and adolescents aged from 3 years...
Share
Rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) space in the three major markets (3MM): the US, Germany, and Japan. These therapies are projected to capture more than 90% of market share in this region by 2030 due to their potential to improve patient convenience and...
Share
A mobile phone app can place the accurate measurement of children’s height in the hands of parents and caregivers. Preliminary data presented at the Society for Endocrinology annual conference in Edinburgh suggests that the app could reliably identify treatable growth disorders much earlier, with significant improvements in child health. Childhood growth is a strong indicator...
Share
Baseline insulin-like growth factor-1 (IGF-1) and stimulated peak growth hormone response can serve as predictors for how severe growth hormone deficiency is in pediatric patients as well as how these patients will respond to different treatments, according to a study recently published in the Journal of the Endocrine Society. Researchers led by Michael O. Thorner,...
